Skip to main content

Chemicon Enters Gene-Targeting Agreement with Genome Biosciences

NEW YORK, Nov. 18 (GenomeWeb News) - Chemicon International, a division of Serologicals, said today that it has entered into an exclusive licensing agreement for Genome BioSciences' Positive-Positive Selection (PPS) gene-targeting technology.

Under the agreement, Chemicon will have the exclusive right to use the PPS technology for generating genetically modified cell lines and mice for its customers. Chemicon said it will also retain exclusive rights to grant third-party technology sublicenses to the PPS technology.

In addition, Rob Burgess, Genome BioSciences President, will join Chemicon as senior director of functional genomics while remaining a director of Genome BioSciences.

Financial terms of the licensing agreement were not disclosed.

Chemicon said that Genome BioSciences' technology is "the first in a series of platform technologies" it expects to license in support of a new functional genomics initiative at the company.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.